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We investigated the effects of interleukin-2 (IL-2) exposure on T-cell signal transduction molecules and apoptosis markers in tumour-
infiltrating lymphocytes (TIL) isolated from 20 melanoma and 16 colorectal carcinoma metastases and expanded in vitro for
therapeutic reinfusion. Before IL-2 culture, TIL showed undetectable or very low levels of T-cell receptor (TCR) e chain, p56
lck, Fas
ligand (FasL) and Bax expression, while Bcl-2 values were elevated. Cancer cells were characterised by low or absent Fas and Bcl-2
and high Bax expression. Notably, they also expressed FasL. After 41–48 days of IL-2 culture, TCR e chain and p56
lck expression of
TIL rose to median values of approximately 80 and 30% positive cells, respectively (Po0.001), FasL expression was detected in 45%
cells from melanomas (Po0.001) and in 3% from colorectal carcinomas (P¼0.09), and Bax-positive cells increased from 17.5 to 70%
(P¼0.005). Moreover, TCR z chain-positive cells were significantly increased from baseline (P¼0.001), Bcl-2-positive cells dropped
from 50 to 1% (P¼0.007) and perforin content was high, while Fas expression was not significantly modified by IL-2 culture. In
conclusion, our data suggest that the degree of immunosuppression in TIL from melanomas and colorectal carcinomas is very high,
and the apoptosis markers’ repertoire of cancer cells resembles that of immune-privileged tissue. Interleukin-2 culture appears to
restore lymphocyte activation mechanisms, resulting in consistent FasL expression and perforin production.
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Although the immune system has the ability to recognise and kill
tumour cells through its lymphoid effectors, as shown by the
findings of both in vitro and in vivo studies (Topalian and
Rosenberg, 1989), it is well known that cancer patients generally
have an inadequate antitumour response. Probably several
mechanisms underlie the lack of efficient spontaneous immune
reactions observed in cancer patients and are responsible for the
poor response rates to immunotherapy (Oliver and Nouri, 1992;
Sulitzeanu, 1993; Atkins et al, 1999). For many years, researchers
have focused attention on the effects of tumour-induced im-
munosuppression on T lymphocytes infiltrating, or associated
with, solid tumours (Whiteside, 1999). There is evidence from
numerous investigations that tumour-infiltrating lymphocytes
(TIL) isolated from a wide range of tumours are functionally
impaired, as manifested by decreased proliferative responses and
decreased ability to mediate cytotoxicity (Whiteside, 1992;
Miescher et al, 1998). Abnormalities in signal transduction
molecules associated with T-cell receptor (TCR) function have
been identified as one of the main mechanisms by which the
tumour microenvironment affects immune cells. In particular,
reduced expression of TCR-associated z chain is one of the more
consistent findings. Initially discovered in TIL of mice bearing
colon carcinoma MCA-38 cells (Mizoguchi et al, 1992), abnorm-
alities in z chain expression were then isolated in TIL of patients
with various types of cancer, including colorectal carcinoma, renal
cell carcinoma and metastatic melanoma (Finke et al, 1993;
Nakagomi et al, 1993; Rabinowich et al, 1996). It has been shown
that decreased or absent expression of the z chain results in
signalling defects in TIL or tumour-associated lymphocytes (TAL),
such as altered expression of the tyrosine kinase p56
lck and a
decreased ability to mobilise intracellular Ca
2+ in response to
activation signals (Mizoguchi et al, 1992; Finke et al, 1993;
Nakagomi et al, 1993; Lai et al, 1996; Rabinowich et al, 1996).
Altered z chain is also associated with impaired cytokine
production, as shown by decreased mRNA and protein levels of
interleukin 2 (IL-2) and interferon-g (Rabinowich et al, 1996) in T
cells. It has been suggested that z chain degradation in TIL and
TAL is caused by tumour-induced activation of intracellular
peptidases in T cells, and that this process may ultimately lead to a
caspase-dependent apoptotic cascade in activated lymphocytes
(Rabinowich et al, 1998; Whiteside, 1999). The biological
significance of z chain degradation has recently been confirmed
by the results of a retrospective study conducted in patients with
oral carcinoma, where low or absent z chain expression in TIL was
found to predict poor survival, independently of other factors
(Reichert et al, 1998).
Another mechanism that may be playing an important role in
mediating tumour-induced immunosuppression is the Fas/FasL
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spathway (Whiteside and Rabinowich, 1998). Recent studies have
shown that tumour cells can assume characteristics similar to
those of immune-privileged tissues such as the low expression or
absence of surface Fas receptor (Fas) and the expression of Fas
ligand (FasL) (Hahne et al, 1996; Nagata, 1996; O’Connell et al,
2001). In addition to other mechanisms (i.e. inhibitory cytokines),
tumour FasL surface expression may contribute to T-cell damage
and apoptosis (Whiteside and Rabinowich, 1998). However, this
hypothesis, formulated on the basis of several authors’ indepen-
dent observations (Whiteside, 1999; Restifo, 2000), has yet to be
confirmed.
The finding that tumour-induced degradation of signalling
molecules can be ‘reverted’, and proliferative and cytotoxic
activities of TIL restored by culture with exogenous cytokines
(especially IL-2), at least in vitro, has important potential
therapeutic implications (Salvadori et al, 1993; Rabinowich et al,
1996; Zier et al, 1996), although data about the in vivo effects of
cytokines administration on T-cell signalling molecules of cancer
patients are still scarce (Farace et al, 1994; Rabinowich et al, 1996).
In the present study, we carried out a multiparameter analysis of
TIL used for therapeutic reinfusion in patients with advanced
melanoma and colorectal cancer who had previously undergone
metastasectomy. In particular, we evaluated TCR z and e chains,
p56
lck, Bcl-2 and Bax expression, FasL and Fas expression on
the surface of TIL from surgically obtained tumour samples, and
reassessed the same parameters, with the addition of perforin, after
TIL were coincubated with IL-2. In parallel, apoptosis markers in
cancer cells of surgically obtained specimens were also examined.
The aims of the study were to provide an overview of the
parameters involved in the mechanisms of immunosuppression in
human TIL from melanomas and colorectal carcinomas cultivated
for therapeutic purposes and to assess the in vitro effects of
exogenous IL-2 on such parameters.
MATERIALS AND METHODS
Patients
From February 1993 to December 1999, 63 patients with advanced
melanoma or colorectal cancer who had undergone metastasect-
omy were treated with TIL plus IL-2. Clinical results of this trial
have been described elsewhere (Ridolfi et al, 1998). The clinical–
biological study was examined and approved by the Ethics
Committee of the Local Health and Social Services (Azienda
USL, Forli’) in accordance with the ethical standards laid down in
the 1964 Declaration of Helsinki. All patients gave their informed
written consent to receive treatment.
This biological study was performed in the last 36 consecutive
patients, whose median age was 54 years (range 23–70). Patient
and tumour characteristics are shown in Table 1.
TIL culture and expansion
Tissue obtained from metastatic lesions was mechanically
fragmented and incubated for 2–16h in a solution of enzymes
containing collagenase (type IV 0.1%), hyaluronidase (type V
0.01%) and DNase (type I 0.00007%). Mononuclear cells were
separated according to density gradients. The cell suspension
obtained was cultured at a concentration of 1 10
6cellsml
 1 in
multiwells using AIM-V medium (Gibco BRL, Grand Island, NY,
USA) supplemented with 6000 UI/ml
 1 recombinant IL-2. Cells
were diluted to a concentration of 1 10
6ml
 1 every 3–4 days.
The cell culture was transferred to culture bags (Baxter-Fenwal,
Deerfield, IL, USA) once the total number of cells had exceeded
0.5–1 10
9. Phenotyping and immunohistochemical analysis were
carried out to check for the presence of residual tumour cells. An
aliquot of the cell suspension was cultured without IL-2 to allow
tumour cell growth. Suspensions of tumour cells and TIL were
cryopreserved in liquid nitrogen in 10% dimethylsulphoxide and
90% foetal calf serum for subsequent studies. When cell numbers
had exceeded 1 10
10, the lymphocytes were concentrated using a
CS 3000 Baxter cell separator and reinfused with IL-2 into the
patient over 2–3h. Screening for contaminating microorganisms
was performed on the cell suspension 48h before reinfusion.
Tumour-infiltrating lymphocytes in the original tumour specimen
are referred to as TIL-1, while lymphocytes at the end of the
culture described above are referred to as TIL-2. TIL-2 median
culture periods were 41 days (range, 33–62) for melanoma and 48
days (range, 36–74) for colorectal carcinoma.
Cell line culture
Chronic human myelogenous leukaemia (K562), human Burkitt
lymphoma (Daudi), acute human T-cell leukaemia (Jurkat), acute
human lymphoblastic leukaemia (MOLT-4) and human promye-
locytic leukaemia (HL-60) cell lines were obtained from Istituto
Zooprofilattico Sperimentale (Brescia, Italy). All cell lines were
maintained in complete RPMI-1640 medium (RPMI-1640 supple-
mented with 10mML -glutamine, 10mgml
 1 streptomycin,
100Uml
 1 penicillin (all from Mascia Brunelli, Milan, Italy)) and
10% heat-inactivated foetal calf serum (561C for 30min) (Gibco
BRL). The above cell lines were used as positive controls for the
various monoclonal antibodies (mAbs).
Monoclonal antibodies
The following panel of mAbs was used: 6B10.2 (anti-CD3 z, 1:150
dilution), UCH-T1 (anti-CD3 e, 1:125 dilution), 3A5 (anti-p56
lck,
1:100 dilution), C-20 (anti-CD95, 1:300 dilution), C-20 (anti-
CD95L, 1:400 dilution), N-20 (anti-CD95L, 1:350 dilution) (all
from Santa Cruz Biotechnology, Santa Cruz, CA, USA), 124 (anti-
Bcl-2, 1:50 dilution), APO-1 (anti-CD95, 1:20 dilution), DT-T1
(anti-CD43, 1:50 dilution), rabbit anti-human T cell (anti-CD3 e,
1:50 dilution) (all from Dako Co., Carpinteria, CA, USA), rabbit
anti-Bax (1:1000 dilution) (PharMingen, San Diego, CA, USA).
Each antibody was titrated on positive stabilised cell lines for the
parameters evaluated to find the correct dilution needed to detect
the specific sites. Two different clones were used for CD95 and
CD95L and both produced almost identical results. The results
reported in the present study refer only to the use of C-20 (anti-
CD95) and N-20 (anti-CD95L) (Smith et al, 1998; Mottolese et al.
2000).
Immunocytochemical (ICC) and immunohistochemical
(IHC) stainings
Immunocytochemical staining was performed on TIL-2 and IHC
staining on TIL-1 and on the tumour cells of the surgically
removed specimen. Tumour-infiltrating lymphocyte immuno-
staining was carried out at the moment of reinfusion on both
cytocentrifuged slides and paraffin-embedded tissue derived from
the tumours treated to obtain TIL expansion. Tumour-infiltrating
lymphocyte cell suspensions were cytocentrifuged at 800rpm for
10min on adhesive glass slides using a Shandon centrifuge
(Shandon Inc., Pittsburgh, PA, USA). Cytospins were air-dried,
fixed with acetone for 10min and stained with the various
antibodies. Sections (5mm thick) obtained from paraffin blocks of
tissue fixed in 10% neutral buffered formalin were mounted on
positive-charged slides (Bio-Optica, Milan, Italy) and then
deparaffinised.
With the exception of CD43 and Bax, all antigens underwent
antigen retrieval (microwaved in 10mM citrate buffer (pH 6.0) for
15min at a medium–high setting). Endogenous peroxidase was
inactivated with 3% hydrogen peroxide, and aspecific sites were
inactivated with bovine serum albumin (BDH Laboratory Supplies,
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British Journal of Cancer (2003) 88(2), 320–326 & 2003 Cancer Research UKPoole, Dorset, UK) in phosphate-buffered saline (PBS concentra-
tion NaCl 130mM;N a 2HPO4, 12H2O6 m M;K H 2PO4 1.55mM)i n
both histological sections and cytospins. The samples were
incubated at room temperature for 1h with different antibodies.
Staining was performed according to the manufacturer’s instruc-
tions using the LSAB
+ peroxidase complex kit (Dako Co.).
Immunoreactivity was visualised with 2,20-azino-bis(3-ethyl-
benthiazoline-6-sulphonic acid) (Dako Co.) and the samples were
counterstained briefly with haemotoxylin. Positive controls con-
sisting of tonsillar sections, cytospins and tumour cell line paraffin
blocks were stained with the different antibodies. Immune serum
was omitted in negative controls. Total lymphocytes were
identified by the expression of CD43 (Borche et al, 1987), and
the proportion of CD43-positive cells was always higher than 70%
both for TIL-1 and TIL-2. CD43 found in TIL-1 and TIL-2 had
median values of about 90%, thus confirming that the tests were
performed mainly on lymphocytes.
In previous experiments, we tested the sensitivity of the IHC
method used in the study by comparing the results obtained with
frozen tissue and paraffin-embedded tissue from 20 cases of
melanoma or renal carcinoma using different dilutions of
antibodies. Similar results were observed with the two processing
techniques at the dilutions used in the present study. Furthermore,
in cell suspensions from the tumour cell lines, we compared the
results obtained by using cytocentrifuged slides vs paraffin-
embedded cell blocks. Again, the results were similar (Ridolfi
et al, unpublished data).
Identification and expression of perforin
TIL perforin expression was determined at the moment of
reinfusion. Lymphocytes (1 10
6) were fixed with 2% cold
paraformaldehyde solution (Sigma, St Louis, MO, USA) and
resuspended in PBS containing 0.2% Tween-20 to permeabilise
cells. The lymphocytes were then washed and incubated with d G9
monoclonal antibody (anti-human perforin) conjugated with
fluorescein isothiocyanate (FITC), resuspended in 1% paraformal-
dehyde and analysed. Negative control cells were incubated only
with FITC-conjugated goat anti-mouse Ig. Flow cytometry analysis
was performed with a FACStar Plus (Becton Dickinson, San Jose,
CA, USA) flow cytometer, calibrated for fluorescence intensity
measurements using FITC-labelled microbead standards (fluores-
cence-activated cell sorting) with assigned MESF values (molecules
of equivalent soluble fluorochrome). Lymphocytes were selected
using polygonal windows that excluded cell aggregates, debris and
morphologically aberrant elements. 5 10
3 cells were analysed for
each sample.
FACS analysis
TIL were phenotyped with monoclonal antibodies recognising
CD3, CD4, CD8, CD16, CD56, CD19, CD25, CD71 and HLA-DR
after in vitro expansion. Lymphocytes were suspended in Hank’s
balanced salt solution (without phenol red), incubated with each
monoclonal antibody for 20min in the dark and then washed.
Cytotoxicity analysis
A cytotoxic assay was performed on TIL-2 from a small number of
melanoma cases (7/20) using the
51Cr release assay just before
patient reinfusion. Target cells included fresh (or cryopreserved)
autologous or allogenic tumour cells, and K562 cells. TIL cytolytic
activity was determined by plating 1000 target cells labelled with
51Cr in V-bottom microtitre plates. Effector cells were then added
at various concentrations to achieve effector:target ratios of
100:1, 50:1, 25:1 and 12:1. Microtitre plates were incubated in a
humidified incubator with 5% CO2 for 4h, then 100mlwell
 1 of
supernatant was removed and their radioactivity counted in a
scintillator. Lysis percentage was calculated according to the
following formula:
Specific lysis % ¼
Experimental release   spontaneous release
Maximum release   spontaneous release
  100:
Statistical analysis
The Wilcoxon pairwise rank tests were used to analyse the
variations in the values of the biological parameters observed in
TIL-1 and TIL-2. Spearman’s nonparametric correlation coefficient
was used to investigate the relation between the different
biomarkers. All P-values were based on two-sided testing (thresh-
old value¼0.05), and statistical analyses were carried out with the
SPSS package.
The study was conducted with a purely exploratory intent.
Multiple tests were performed on this limited case series,
increasing the risk of finding statistical differences that were due
to chance. As no statistical correction was made, the P-value must
be interpreted with caution.
RESULTS
The expression of T-cell transduction signals and apoptosis
markers was analysed in TIL before (TIL-1) and after (TIL-2) in
vitro culture with IL-2 in 20 patients with advanced melanoma and
in 16 with advanced colorectal cancer (Table 1).
Signal transduction molecules
The data regarding signal transduction activating molecules in
TIL-1 and TIL-2 are shown in Figure 1. We observed an increase in
the expression of e and z chains and p56
lck after culture with IL-2.
In particular, p56
lck and the e chain had a very low or null
expression in TIL-1, which increased up to 100% positive cells
after exposure to IL-2 (TIL-2). T-cell receptor z chain expression
was significantly higher after culture, although some patients
(those with high pretreatment values) showed no evidence of an
increase at the end of culture. The low level of expression of T-cell
signal transduction molecules in TIL-1 and the increase produced
by in vitro culture in the presence of IL-2 were observed in both
melanoma and colorectal carcinoma patients.
Table 1 Patient and tumour characteristics
Melanoma Colorectal carcinoma
Patient number 20 16
Male 11 14
Female 9 2
Advanced patients
a 83
NED patients
b 12 13
Metastases removed
Lymph nodes 13
Skin 5
Liver 11
Lung 2 3
Adrenal 1
Peritoneum 1
aPatients with evidence of disease after metastasectomy.
bPatients without evidence of disease after metastasectomy.
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The data regarding apoptosis markers in TIL-1 and TIL-2 are
shown in Figure 2. IL-2 induced a considerable increase in FasL
expression, which was absent in TIL-1, whereas Fas expression was
not significantly modified. Bcl-2 and Bax levels showed, as
expected, inverse changes: the median percentage of Bcl-2-positive
cells dropped from 50 to 1 (P¼0.007) and, in parallel, median
Bax-positive cell percentages rose from 17.5 to 70 (P¼0.005).
Fas receptor, FasL, Bcl-2 and Bax expression determined in
tumour cells from surgically removed metastases is shown in
Table 2. Median values were similar for the two tumour types and
showed low or absent Fas and Bcl-2 expression, appreciable levels
of FasL and very high levels of Bax expression. However, there was
a great variation in apoptosis marker levels among individual
specimens.
TIL activation determinants
The extent of TIL activation after culture with IL-2 was analysed by
testing the surface determinants and the level of perforin.
TIL-2 phenotypes, measured by FACS analysis, showed a similar
percentage of positive cells for melanoma and colorectal carcino-
ma with regard to CD4, CD8, CD56 and HLA-DR. As reported in
the literature (Rosenberg et al, 1994; Goedegebuure et al, 1995),
the TIL phenotype consisted mainly of CD8 (median value 84%:
range 14–98) and HLA-DR (median value 66%: range 13–98)
positive cells (Table 3).
Perforin levels in the supernatant were determined at median
culture periods of 41 (range 33–62) and 48 (range 36–74) days for
TIL from melanomas and colorectal carcinomas, respectively, and
were elevated in both tumour types, especially in TIL from
colorectal carcinomas (median MESF 22,118; range 10000–
81000).
Cytotoxicity
In the few TIL-2 melanoma cases (7/20) in which cytotoxicity was
assessed, a low reactivity against K562 cells was generally found,
while the reactivity against autologous melanoma cells was slightly
higher. It remained, however, at around 20% of lysis (Table 4).
Statistical correlations among different parameters
Statistical analysis was performed using Spearman’s correlation
coefficient to investigate the relation between the different TIL
biomarkers before and after exposure to IL-2. In Table 5 only
statistically significant correlations are shown. In brief, before IL-2
exposure, there was a negative correlation between Fas and Bax
expression in TIL from both melanoma and colon carcinoma, and
a positive correlation between Fas and FasL only in TIL from
colorectal carcinoma. Following IL-2 exposure, a far larger number
of significant correlations were observed for the TIL from both
tumour types. Fas expression was positively correlated with p56
lck
in melanoma TIL, and with p56
lck and the z chain in colorectal TIL.
Fas ligand was positively correlated with the z and e chains and
p56
lck in melanoma TIL, and only with the e chain and p56
lck in
colorectal carcinoma TIL. Moreover, a significant positive
correlation was observed between perforin expression and p56
lck,
and perforin and the z chain in melanoma TIL.
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Figure 1 Signal transduction molecules. The percentage of positive lymphocytes was evaluated before (TIL-1) and after (TIL-2) culture with IL-2. TCR, z
and e chains and p56
lck expression was evaluated in TIL-1 by IHC staining on paraffin-embedded surgically removed specimens. The same molecules were
evaluated in TIL-2 by IHC staining on cytocentrifuged slides. The assays were performed on 20 melanoma and 16 colon carcinoma samples.
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Our observations of TCR-associated signalling molecules and
apoptosis markers in TIL obtained from melanoma and colorectal
carcinoma metastases support the hypothesis that lymphocytes at
the tumour site manifest a high degree of immunosuppression, as
shown by absent e chain or p56
lck expression, very low z chain and
Fas expression, and, most importantly, extremely low FasL
expression. As for the tumour cells, they also had very low Fas
but, in contrast, showed a relatively high level of FasL expression.
The scenario would therefore seem to be one of strong
immunosuppression in TIL conditioned by tumour cells that
appear to be very similar to immune-privileged tissue. Abnorm-
alities in TCR-associated molecules, especially z chain and p56
lck,
have been consistently reported in several investigations carried
out on TIL or TAL obtained from cancer patients (Finke et al,
1993; Nakagomi et al, 1993; Lai et al, 1996; Rabinowich et al, 1996),
as well as tumour-bearing mice (Mizoguchi et al, 1992). The
possibility has been suggested that these signalling defects may be
artefacts because of processing techniques. However, in our study
(as in other investigations), such abnormalities were detected in
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Figure 2 Apoptosis-related molecules. The percentage of positive lymphocytes was evaluated before (TIL-1) and after (TIL-2) culture with IL-2. Fas
receptor, FasL, Bcl-2 and Bax expression was evaluated in TIL-1 by IHC staining on paraffin-embedded, surgically removed specimens. The same molecules
were evaluated in TIL-2 by IHC staining on cytocentrifuged slides. The assays were performed on 20 melanoma and 16 colorectal carcinoma samples.
Table 2 Apoptosis markers in tumour cells: percentage of positive cells
Melanoma Colorectal carcinoma
Median (%) Range Median (%) Range
Fas 1.5 0–25 0.5 0–15
FasL 35 0–80 22.5 0–80
Bcl-2 5 0–80 0 0–65
Bax 80 0–90 70 5–90
Apoptosis markers were evaluated by immunohistochemical staining on the tumour
cells present in paraffin-embedded surgically removed specimens.
Table 3 Phenotypes of TIL-2 from melanoma and colorectal carcinoma
metastases: percentage of positive cells
Melanoma Colorectal carcinoma
Median (%) Range Median (%) Range
CD4 1.5 0–68 6 0–96
CD8 84 14–98 73.5 0–99
CD56 16 2–75 8 2–35
HLA-DR 66 13–98 61 25–99
Table 4 TIL-2 cytolytic assay (% of lysis) in seven patients with
melanoma
Patient
K562
cells
Allogenic
melanoma cells
Autologous
melanoma cells
11 4 1 6
2 2 20 21
32 3 –
41 2 3 1 2
52 2 1 8
62 8 1 5 2 9
77 1 1 5
Ratio effector : target=25 : 1
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processing.
Our results with IL-2-cultured TIL are consistent with the
hypothesis of an IL-2-induced modulation of the markers involved
in activation mechanisms, manifesting as a restoration of the e and
z chains and, to a lesser degree, of p56
lck expression, an increase in
FasL expression and an elevated perforin production. The results
of the cytotoxic assay, although limited to a small number of cases,
appear to support the notion that IL-2-stimulated TIL actually
possess a specific cytotoxic activity. Similar patterns of restored
activation molecules after IL-2 culture were observed in melanoma
and colorectal carcinoma TIL.
After IL-2 culture in melanoma TIL, high levels of Fas and Bax
and low Bcl-2 expression were observed. These findings suggest
that IL-2 is an important growth and survival factor for T
lymphocytes and that it also sensitises these cells to Fas-mediated
cell death. The different patterns of Fas and Bcl-2 expression in
TIL-2 from colon carcinomas and melanomas could be attributed
to different homeostatic conditions in rapidly expanding cell
cultures since these two markers are apoptosis related (Van Parijs
et al, 1999). However, it should be highlighted that tumour Fas and
FasL, and Bcl-2 and Bax systems were similar in the two tumour
types. In particular, we observed a low expression of Bcl-2 proto-
oncogene and a high expression of Bax, in agreement with the
literature data (Tang et al, 1998). The role of Bcl-2 in malignant
transformations is still controversial (Tron et al, 1995; Selzer et al,
1998), whereas there is evidence to suggest that Bcl-2 expression
could be an indicator of lymph node and distant metastases
(Grover and Wilson, 1996; Hernberg et al, 1998). There are
conflicting opinions about the role of tumour FasL in mediating
apoptosis of immune cells and counterattacking the host’s defence
systems (Rivoltini et al, 1998; Chappell et al, 1999; Restifo and
Rosenberg, 1999; O’Connell et al, 2001). In a recent review,
Whiteside and Rabinovich suggest that the tumour may directly
induce post-translational modifications of signal-transducing
proteins, such as the z chain, in T lymphocytes, and that these
processes may be a part of the apoptotic cascade initiated in T cells
by contact with the tumour cells. They also suggest that both
degradation of signalling molecules and apoptosis of T cells may
be mediated by the Fas/FasL pathway (Whiteside and Rabinovich,
1998).
In conclusion, the findings of our investigation, in agreement
with accumulated evidence from numerous studies, lend support
to the hypothesis that the tumour microenvironment induces
immunosuppression of infiltrating lymphocytes by downregulat-
ing signalling molecules and apoptosis markers. Such alterations,
however, can be reverted by removal of TIL from the tumour site
and coincubation with IL-2. This ‘rescue’ from local immunosup-
pressive mechanisms appears to be crucial if the cytotoxic
potential of TIL is to be exploited for therapeutic purposes.
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